Quantum-Si Q4 revenue declines

Quantum-Si

03/03/2026 21:40

Overview

Proteomics tech firm's Q4 revenue was $451,000, vs $1.1 mln year ago

Company announced Proteus platform list price of $425,000

Operating expenses decreased yr/yr due to cost discipline and focused resource allocation

Outlook

Quantum-Si expects 2026 revenue of approximately $1.0 mln

Company anticipates adjusted total operating expenses of $98.0 mln or less in 2026

Quantum-Si projects total cash usage of $93.0 mln or less in 2026

Result Drivers

COST DISCIPLINE - Operating expenses decreased yr/yr due to cost discipline and focused resource allocation

Company press release: ID:nBw4NdXW0a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$451,000
Q4 EPS
-$0.08
Q4 Net Income
-$17.61 mln
Q4 Operating Expenses
$21.22 mln
Q4 Operating Income
-$21.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Quantum-Si Inc is $2.50, about 167.8% above its March 2 closing price of $0.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)